Products for Out-Licensing

Products Available for Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at [email protected] to know more about NAL’s products and partnering opportunities.

Central Nervous System
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL8812 Donepezil 3-Day Patch for Alzheimer’s Disease
505(b)(2) NDA
NAL8817 Donepezil 1-Day ODF for Alzheimer Disease
505(b)(2) NDA
NAL8823 Rivastigmine 1-Day Patch for Alzheimer’s Disease
ANDA
NAL8776 Rotigotine1-Day Patch for Parkinson Disease
ANDA
NAL2516 Selegiline 1-Day Patch for Parkinson's Disease
ANDA
NAL2522 Risperidone Microsphere Injection for Schizophrenia
ANDA
NAL2527 Olanzapine 2/4 Week Injection for Schizophrenia
ANDA
NAL2536 Paliperidone Palmitate 1-Month Injectable for Schizophrenia
ANDA
NAL2538 Paliperidone Palmitate 3-Month Injectable for Schizophrenia
ANDA
NAL2601 Glatiramer Acetate Injection for Multiple Sclerosis
ANDA
Top